Skip to NavigationSkip to content

fda treatment

FDA rejects oleandrin as a dietary supplement, after being touted by major Trump ally as a coronavirus treatment

Photo by the FDA

The FDA has rejected a submission from Phoenix Biotechnology to market oleandrin as a dietary supplement. 

Phoenix Biotechnology submitted oleandrin to the FDA to be approved as a supplement on 2 June. The FDA response letter was sent on 14 August and published last week, saying that as the company had already tested oleandrin as a potential prescription drug it could not seek permission to sell it as a supplement at the same time. 

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches